Brief: Hepion Pharmaceuticals To Present Data On Synergistic Effects Of Rencofilstat With Anti-Pd1 At Aacr 2023
17/04/2023 23:05
April 17 (Reuters) - Hepion Pharmaceuticals Inc
HEPA.O :
* HEPION PHARMACEUTICALS TO PRESENT DATA ON SYNERGISTIC
EFFECTS OF
RENCOFILSTAT WITH ANTI-PD1 AT AACR 2023
Source text for Eikon: ID:nGNX3xsmPY
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement